The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism

Patricia K. Sonsalla, Christal Coleman, Lai Yoong Wong, Suzan L. Harris, Jason R. Richardson, Bharathi S. Gadad, Wenhao Li, Dwight C. German

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of nigrostriatal dopamine (DA) neurons with an accompanying neuroinflammation. The peptide angiotensin II (AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-phenylpyridinium (MPP. +). The accompanying activation of microglia in the substantia nigra of MPP. +-treated rats was reduced by the chronic captopril treatment. These findings indicate that captopril is neuroprotective for nigrostriatal DA neurons in both acute and chronic rodent PD models. Targeting the brain AngII pathway may be a feasible approach to slowing neurodegeneration in PD.

Original languageEnglish (US)
Pages (from-to)376-383
Number of pages8
JournalExperimental Neurology
Volume250
DOIs
StatePublished - Dec 2013

Fingerprint

Dopaminergic Neurons
Captopril
Parkinsonian Disorders
Angiotensin-Converting Enzyme Inhibitors
Parkinson Disease
Animal Models
Substantia Nigra
Angiotensin II
Neurodegenerative Diseases
Rodent Diseases
1-Methyl-4-phenylpyridinium
Angiotensin Type 1 Receptor
Angiotensin Receptors
Brain
Microglia
Peptidyl-Dipeptidase A
Renin-Angiotensin System
Dopamine
Oxidative Stress
Peptides

Keywords

  • Angiotensin converting enzyme
  • Captopril
  • Dopamine neurodegeneration
  • Mice
  • Microglia
  • MPP+
  • MPTP
  • Osmotic minipump
  • Parkinson's disease
  • Rats

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. / Sonsalla, Patricia K.; Coleman, Christal; Wong, Lai Yoong; Harris, Suzan L.; Richardson, Jason R.; Gadad, Bharathi S.; Li, Wenhao; German, Dwight C.

In: Experimental Neurology, Vol. 250, 12.2013, p. 376-383.

Research output: Contribution to journalArticle

Sonsalla, Patricia K. ; Coleman, Christal ; Wong, Lai Yoong ; Harris, Suzan L. ; Richardson, Jason R. ; Gadad, Bharathi S. ; Li, Wenhao ; German, Dwight C. / The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. In: Experimental Neurology. 2013 ; Vol. 250. pp. 376-383.
@article{a7e5b586c8b54e0c9a87c7beaeddfb97,
title = "The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism",
abstract = "Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of nigrostriatal dopamine (DA) neurons with an accompanying neuroinflammation. The peptide angiotensin II (AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-phenylpyridinium (MPP. +). The accompanying activation of microglia in the substantia nigra of MPP. +-treated rats was reduced by the chronic captopril treatment. These findings indicate that captopril is neuroprotective for nigrostriatal DA neurons in both acute and chronic rodent PD models. Targeting the brain AngII pathway may be a feasible approach to slowing neurodegeneration in PD.",
keywords = "Angiotensin converting enzyme, Captopril, Dopamine neurodegeneration, Mice, Microglia, MPP+, MPTP, Osmotic minipump, Parkinson's disease, Rats",
author = "Sonsalla, {Patricia K.} and Christal Coleman and Wong, {Lai Yoong} and Harris, {Suzan L.} and Richardson, {Jason R.} and Gadad, {Bharathi S.} and Wenhao Li and German, {Dwight C.}",
year = "2013",
month = "12",
doi = "10.1016/j.expneurol.2013.10.014",
language = "English (US)",
volume = "250",
pages = "376--383",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism

AU - Sonsalla, Patricia K.

AU - Coleman, Christal

AU - Wong, Lai Yoong

AU - Harris, Suzan L.

AU - Richardson, Jason R.

AU - Gadad, Bharathi S.

AU - Li, Wenhao

AU - German, Dwight C.

PY - 2013/12

Y1 - 2013/12

N2 - Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of nigrostriatal dopamine (DA) neurons with an accompanying neuroinflammation. The peptide angiotensin II (AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-phenylpyridinium (MPP. +). The accompanying activation of microglia in the substantia nigra of MPP. +-treated rats was reduced by the chronic captopril treatment. These findings indicate that captopril is neuroprotective for nigrostriatal DA neurons in both acute and chronic rodent PD models. Targeting the brain AngII pathway may be a feasible approach to slowing neurodegeneration in PD.

AB - Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a prominent loss of nigrostriatal dopamine (DA) neurons with an accompanying neuroinflammation. The peptide angiotensin II (AngII) plays a role in oxidative-stress induced disorders and is thought to mediate its detrimental actions via activation of AngII AT1 receptors. The brain renin-angiotensin system is implicated in neurodegenerative disorders including PD. Blockade of the angiotensin converting enzyme or AT1 receptors provides protection in acute animal models of parkinsonism. We demonstrate here that treatment of mice with the angiotensin converting enzyme inhibitor captopril protects the striatum from acutely administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrine (MPTP), and that chronic captopril protects the nigral DA cell bodies from degeneration in a progressive rat model of parkinsonism created by the chronic intracerebral infusion of 1-methyl-4-phenylpyridinium (MPP. +). The accompanying activation of microglia in the substantia nigra of MPP. +-treated rats was reduced by the chronic captopril treatment. These findings indicate that captopril is neuroprotective for nigrostriatal DA neurons in both acute and chronic rodent PD models. Targeting the brain AngII pathway may be a feasible approach to slowing neurodegeneration in PD.

KW - Angiotensin converting enzyme

KW - Captopril

KW - Dopamine neurodegeneration

KW - Mice

KW - Microglia

KW - MPP+

KW - MPTP

KW - Osmotic minipump

KW - Parkinson's disease

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=84887551645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887551645&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2013.10.014

DO - 10.1016/j.expneurol.2013.10.014

M3 - Article

C2 - 24184050

AN - SCOPUS:84887551645

VL - 250

SP - 376

EP - 383

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -